Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPS-2071 in Crohn's Disease
NCT03850509Phase 2Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Feb 2020
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of OPS-2071 in Crohn's disease, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Percentage of Participants Who Achieved Clinical Remission Based on Crohn's Disease Activity Index (CDAI) Score at Week 12. Started Feb 2020; status: terminated.
02
Drugs
OPS-2071
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03850509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850509.